Surgical Management of Sarcoma Metastatic to Liver

Brett L. Ecker, Robert G. Maki, Michael J. Cavnar, Ronald P. DeMatteo

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Sarcomas are rare mesenchymal tumors with a propensity for hematogenous metastasis. Gastrointestinal stromal tumor (GIST) is the most common histologic subtype and the most common source of hepatic metastases. In the case of metastatic GIST, neoadjuvant imatinib can be used as a selection tool for the judicious application of surgery, where treatment-responsive patients who undergo resection to prevent the development of treatment-resistant clones have associated 10-year actuarial survival of 40%. Further advances for many of the non-GIST sarcoma subtypes will depend on the development of improved systemic therapies and evaluation of their activity in subtype or molecularly defined trials.

Original languageEnglish
Pages (from-to)57-67
Number of pages11
JournalSurgical Oncology Clinics of North America
Issue number1
StatePublished - Jan 2021

Bibliographical note

Funding Information:
Drs B.L. Ecker, M.J. Cavnar, and R.P. DeMatteo do not have any relevant conflicts of interest to disclose. Dr R.G. Maki reports research support to the institution from SARC: Sarcoma Alliance for Research through Collaboration.

Publisher Copyright:
© 2020 Elsevier Inc.


  • GIST
  • Gastrointestinal stromal tumor
  • Hepatic tumor
  • Imatinib
  • Metastasis
  • Sarcoma

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Surgical Management of Sarcoma Metastatic to Liver'. Together they form a unique fingerprint.

Cite this